# A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

> **NCT07720193** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanjing Leads Biolabs Co.,Ltd** · enrollment: 280 (estimated)

## Conditions studied

- Advanced Extrapulmonary Neuroendocrine Carcinoma

## Interventions

- **DRUG:** LBL-024 for Injection
- **DRUG:** Etoposide injection
- **DRUG:** Cisplatin injection
- **DRUG:** Carboplatin injection
- **DRUG:** LBL-024 placebo for injection

## Key facts

- **NCT ID:** NCT07720193
- **Lead sponsor:** Nanjing Leads Biolabs Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-22
- **Primary completion:** 2030-12-22
- **Final completion:** 2030-12-22
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720193, "A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*